We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

63 hedge funds and large institutions have $43M invested in Cue Biopharma in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

101% more call options, than puts

Call options by funds: $207K | Put options by funds: $103K

23% more capital invested

Capital invested by funds: $35.1M → $43M (+$7.97M)

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

3% more funds holding

Funds holding: 61 → 63 (+2)

0.06% less ownership

Funds ownership: 0.99% → 0.93% (-0.06%)

24% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 17

Holders
63
Holders Change
+2
Holders Change %
+3.28%
% of All Funds
1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
13
Reduced
17
Closed
9
Calls
$207K
Puts
$103K
Net Calls
+$104K
Net Calls Change
-$22K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$435K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$421K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$396K
4
Citadel Advisors
Citadel Advisors
Florida
+$285K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$280K

Top Sellers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
-$2.19M
2
GCP
GSA Capital Partners
United Kingdom
-$366K
3
CC
Carlson Capital
Texas
-$353K
4
BL
Bleichroeder LP
New York
-$338K
5
Renaissance Technologies
Renaissance Technologies
New York
-$288K
Name Holding Trade Value Shares
Change 		Change in
Stake
Group One Trading
51
Group One Trading
Illinois
$5.63K +$5.05K +53 New
BHWM
52
Beaird Harris Wealth Management
Texas
$2.85K – – –
PMEF
53
Point72 Middle East FZE
United Arab Emirates
$2.31K +$2.1K +22 New
KFS
54
Kelly Financial Services
Massachusetts
$1.78K – – –
HI
55
Harbour Investments
Wisconsin
$1.57K – – –
AWM
56
Accel Wealth Management
Iowa
$1.14K – – –
JMF
57
Johnson Midwest Financial
Iowa
$1.07K +$954 +10 New
SS
58
Sunbelt Securities
Texas
$839 +$763 +8 New
ASN
59
Advisory Services Network
Georgia
$714 – – –
AAG
60
Armstrong Advisory Group
Massachusetts
$429 – – –
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
$346 -$286 -3 -50%
Osaic Holdings
62
Osaic Holdings
Arizona
$202 -$6.39K -67 -97%
Jacobs Levy Equity Management
63
Jacobs Levy Equity Management
New Jersey
– -$198K -2,317 Closed
SMH
64
Sanders Morris Harris
Texas
– -$161K -1,881 Closed
Acadian Asset Management
65
Acadian Asset Management
Massachusetts
– -$104K -1,239 Closed
Bank of Montreal
66
Bank of Montreal
Ontario, Canada
– -$98K -1,130 Closed
Qube Research & Technologies (QRT)
67
Qube Research & Technologies (QRT)
United Kingdom
– -$82.1K -960 Closed
Connor, Clark & Lunn Investment Management (CC&L)
68
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$65.5K -766 Closed
JF
69
Jump Financial
Illinois
– -$33.1K -388 Closed
AWM
70
Accurate Wealth Management
Florida
– -$7.6K -85 Closed
MCC
71
Money Concepts Capital
Florida
– -$2.04K -24 Closed
1 2
3

CUE Hedge Fund Activity: Q1 2023 in Review

63 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2023, worth a combined $43M — up 23% from $35.1M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CUE positions and 9 closed out — a net gain of 2 holders — while 13 added to existing stakes and 17 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $435K. The largest seller was Prosight Management, cutting an estimated $2.19M.

  • 63 institutional investors held Cue Biopharma (CUE) as of Q1 2023, up from 61 in Q4 2022.
  • Funds reported $43M of Cue Biopharma stock for Q1 2023, up 23% quarter-over-quarter.
  • 11 funds opened new Cue Biopharma positions in Q1 2023 and 9 closed out, a net change of +2 holders.
  • The largest Cue Biopharma buyer in Q1 2023 was Geode Capital Management, an estimated $435K added.
  • The largest Cue Biopharma seller in Q1 2023 was Prosight Management, an estimated $2.19M sold.

Based on aggregated 13F filings for Q1 2023.